Urinary Tract InfectionsPRO30CSPNCT05513677
Characterisation of Biofilm Growth on Coated vs. Uncoated Urinary Catheter Surfaces in Normal Clinical Use
A study testing M4D in people with Urinary Tract Infections, run by Camstent Ltd. at 1 site in United Kingdom.
Trial summary
1. Evaluated Patients: 5 patients (Convenience sample: non-blinded, non-randomised) Selection follows documented hospital protocols for routine catheterisation 2. Measured Patients: 30 patients (Convenience sample: non-blinded and non-randomised) 20 who receive the M4D coated catheter. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Urinary Tract Infections
- What is being tested?
- M4D
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 35 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 14 Aug 2018to 30 Dec 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- -
Who cannot join
- • Patients under age 18.
- Patients that have or recently (within 3 weeks) had a urinary catheter, or those with signs of current urinary tract infection.
- Patients who they have had previous radiation therapy in lower pelvis.
- Patients who are cognitively impaired, or are unwilling to give consent
- Patients with a potentially immunocompromised condition
- Patients that require further antibiotics after initial dose, or those that are administered antibiotics following an infection whilst the trial urinary catheter is in situ
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
The James Cook University Hospital,
Middlesbrough, TS4 3BW
About this study
- Evaluated Patients: 5 patients (Convenience sample: non-blinded, non-randomised) Selection follows documented hospital protocols for routine catheterisation
- Measured Patients: 30 patients (Convenience sample: non-blinded and non-randomised)
- 20 who receive the M4D coated catheter.
- 10 who receive the standard uncoated catheters used in routine patient care.
Read the detailed description
- Evaluated Patients: 5 patients (Convenience sample: non-blinded, non-randomised) Selection follows documented hospital protocols for routine catheterisation
- Measured Patients: 30 patients (Convenience sample: non-blinded and non-randomised)
- 20 who receive the M4D coated catheter.
- 10 who receive the standard uncoated catheters used in routine patient care.
- Evaluation (5 patients, coated catheter)
A convenience sample of patients will be selected to receive the Camstent coated catheter for their routine care. These enrolments are drawn from among those recommended for routine catheterisation, for up to 28 days and in accordance to existing hospital protocols. There is no change to the routine protocols for insertion, maintenance, withdrawal, or documentation of the patient's catheterisation. Following use, the catheter is discarded according to the hospital's procedures.
Staff questionnaires will be completed to capture general use information. These will document the opinions of the nurse inserting and withdrawing the catheter, and may include questions for the patient, to record their experience. There will be no collection of patient information, and no analysis of the discarded catheter.
- Measurement (10 patients receiving uncoated catheters, 20 patients receiving coated catheters)
The data collection will include 10 patients who have received the standard hospital issued uncoated catheter and 20 patients who have received the Camstent coated catheter. There will be no randomisation and no blinding.
The first 10 patients needing routine urinary catheterisation to drain their bladder for up to 28 days whilst in hospital will receive the routine hospital issued catheter and will looked after by hospital and staff as standard practice.
The next 20 patients needing routine urinary catheterisation to drain their bladder whilst in hospital will receive a coated catheter. There will be no change to the intended use of the catheter for patients where it is deemed medically necessary to drain urine from the urinary bladder via the urethra using the catheter device for up to 28 days. There will be no change to any patient care or catheterisation procedures.
All 30 catheters will be sent to a laboratory for surface examination rather than immediately disposed of as medical waste. Harvested catheters will be bagged in an airtight plastic bag and tagged with a record identifier. A record identifier will be used to establish catheter traceability and duration, and will not compromise patient anonymity. The catheter will be kept refrigerated and transported to the analysis laboratory at Nottingham University within two days.
At the Nottingham Laboratory, the catheters will be subjected to qualitative and quantitative analysis to determine the percentage of biofilm coverage on the surface. This will initially be achieved using staining followed by microscopic visual examination of the catheter surface, and images taken of any surface encrustation.
For Fluorescence Microscopy, the procedure will be:
- Cut the catheter into segments then wash three times in ~15 ml of PBS with gentle agitation.
- Transfer the washed catheter segments into the wells of a sterile 24 well plate and stain with SYTO17 Red Fluorescent Nucleic Acid Stain.
- Segments will be imaged using a laser scanning confocal microscope using a 10 X objective lens over a 1024 μm x 1024 μm area.
- A z-section will be imaged (each section is 4μm apart with 36 images taken over 140μm) such that the entire curved surface is imaged. The coverage data will then be taken from a maximum intensity z-projection.
- Data analysis will be carried out in ImageJ using the maximum intensity z-projection images.
- Images will be converted to 8-bit greyscale images, a threshold applied to select the data correctly and the biofilm coverage measured.
- The percentage of coverage for each sample will be computed as (Light) / (Light + Dark) * 100%.
Aggregate descriptive statistics will be calculated, and biofilm coverage will be plotted against the duration of catheterisation as a scattergram. The study is not powered to permit statistical analysis.
Prior laboratory experiments predict that the difference in biofilm coverage could exceed 80%. If larger differences are seen in harvested catheters, then a Total Cell Count assay, in which the biofilm is sonicated free of the surface and then assessed through serial dilution, may be substituted for Fluorescence Microscopy.
- Conditions
- Urinary Tract Infections
- Being tested
- M4D, Standard of Care
- Medical subject headings
- Urinary Tract Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
M4DDevice
Coated catheter
Standard of CareDevice
Standard of Care
| Study group | Role | What they receive |
|---|---|---|
| Standard of Care | Active comparator | Standard of Care Receives: Device: Standard of Care |
| M4D coated catheter | Experimental | Experimental Receives: Device: M4D |
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary outcome is the percentage of catheter surface colonised by biofilm, calculated as (light / (light + dark) x 100% in measurement of stained samples using fluorescence microscopy.
The primary outcome is the percentage of catheter surface colonised by biofilm, calculated as (light / (light + dark) x 100% in measurement of stained samples using fluorescence microscopy.
Measured: 30 days
Secondary outcomes (1)
Secondary outcomes will be logging of events, including catheter blockage or presumed CAUTI.
Secondary outcomes will be logging of events, including catheter blockage or presumed CAUTI.
Measured: 30days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Aug 2022
- Study start14 Aug 2018
- Primary completion20 May 2020
- Study completion30 Dec 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Urinary Tract InfectionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Single group
- Model description
- 1. Evaluated Patients: 5 patients (Convenience sample: non-blinded, non-randomised) Selection follows documented hospital protocols for routine catheterisation 2. Measured Patients: 30 patients (Convenience sample: non-blinded and non-randomised) * 20 who receive the M4D coated catheter. * 10 who receive the standard uncoated catheters used in routine patient care.
- Masking
- None (open label)
- Enrolment
- 35 participants (actual)
Sponsor and investigators
- Lead sponsor
- Camstent Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05513677
- Sponsor's protocol ID
- PRO30CSP
- Acronym
- PRO30CSP
- Status last verified
- Aug 2022
- First submitted
- 22 Aug 2022
- Last updated
- 31 Aug 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Aug 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Characterisation of Biofilm Growth on Coated vs. Uncoated Urinary Catheter Surfaces in Normal Clinical Use
- ClinicalTrials.gov ID
- NCT05513677
- Acronym / sponsor ID
- PRO30CSP / PRO30CSP
- Conditions
- Urinary Tract Infections
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 35 participants (actual)
- Lead sponsor
- Camstent Ltd.Industry (pharma, biotech, devices)
- Study start
- 14 Aug 2018 (actual)
- Primary completion
- 20 May 2020 (actual)
- Study completion
- 30 Dec 2021 (actual)
- First posted
- 24 Aug 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- Evaluated Patients: 5 patients (Convenience sample: non-blinded, non-randomised) Selection follows documented hospital protocols for routine catheterisation
- Measured Patients: 30 patients (Convenience sample: non-blinded and non-randomised)
- 20 who receive the M4D coated catheter.
- 10 who receive the standard uncoated catheters used in routine patient care.
Detailed description
- Evaluated Patients: 5 patients (Convenience sample: non-blinded, non-randomised) Selection follows documented hospital protocols for routine catheterisation
- Measured Patients: 30 patients (Convenience sample: non-blinded and non-randomised)
- 20 who receive the M4D coated catheter.
- 10 who receive the standard uncoated catheters used in routine patient care.
- Evaluation (5 patients, coated catheter)
A convenience sample of patients will be selected to receive the Camstent coated catheter for their routine care. These enrolments are drawn from among those recommended for routine catheterisation, for up to 28 days and in accordance to existing hospital protocols. There is no change to the routine protocols for insertion, maintenance, withdrawal, or documentation of the patient's catheterisation. Following use, the catheter is discarded according to the hospital's procedures.
Staff questionnaires will be completed to capture general use information. These will document the opinions of the nurse inserting and withdrawing the catheter, and may include questions for the patient, to record their experience. There will be no collection of patient information, and no analysis of the discarded catheter.
- Measurement (10 patients receiving uncoated catheters, 20 patients receiving coated catheters)
The data collection will include 10 patients who have received the standard hospital issued uncoated catheter and 20 patients who have received the Camstent coated catheter. There will be no randomisation and no blinding.
The first 10 patients needing routine urinary catheterisation to drain their bladder for up to 28 days whilst in hospital will receive the routine hospital issued catheter and will looked after by hospital and staff as standard practice.
The next 20 patients needing routine urinary catheterisation to drain their bladder whilst in hospital will receive a coated catheter. There will be no change to the intended use of the catheter for patients where it is deemed medically necessary to drain urine from the urinary bladder via the urethra using the catheter device for up to 28 days. There will be no change to any patient care or catheterisation procedures.
All 30 catheters will be sent to a laboratory for surface examination rather than immediately disposed of as medical waste. Harvested catheters will be bagged in an airtight plastic bag and tagged with a record identifier. A record identifier will be used to establish catheter traceability and duration, and will not compromise patient anonymity. The catheter will be kept refrigerated and transported to the analysis laboratory at Nottingham University within two days.
At the Nottingham Laboratory, the catheters will be subjected to qualitative and quantitative analysis to determine the percentage of biofilm coverage on the surface. This will initially be achieved using staining followed by microscopic visual examination of the catheter surface, and images taken of any surface encrustation.
For Fluorescence Microscopy, the procedure will be:
- Cut the catheter into segments then wash three times in ~15 ml of PBS with gentle agitation.
- Transfer the washed catheter segments into the wells of a sterile 24 well plate and stain with SYTO17 Red Fluorescent Nucleic Acid Stain.
- Segments will be imaged using a laser scanning confocal microscope using a 10 X objective lens over a 1024 μm x 1024 μm area.
- A z-section will be imaged (each section is 4μm apart with 36 images taken over 140μm) such that the entire curved surface is imaged. The coverage data will then be taken from a maximum intensity z-projection.
- Data analysis will be carried out in ImageJ using the maximum intensity z-projection images.
- Images will be converted to 8-bit greyscale images, a threshold applied to select the data correctly and the biofilm coverage measured.
- The percentage of coverage for each sample will be computed as (Light) / (Light + Dark) * 100%.
Aggregate descriptive statistics will be calculated, and biofilm coverage will be plotted against the duration of catheterisation as a scattergram. The study is not powered to permit statistical analysis.
Prior laboratory experiments predict that the difference in biofilm coverage could exceed 80%. If larger differences are seen in harvested catheters, then a Total Cell Count assay, in which the biofilm is sonicated free of the surface and then assessed through serial dilution, may be substituted for Fluorescence Microscopy.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- 1. Evaluated Patients: 5 patients (Convenience sample: non-blinded, non-randomised) Selection follows documented hospital protocols for routine catheterisation 2. Measured Patients: 30 patients (Convenience sample: non-blinded and non-randomised) * 20 who receive the M4D coated catheter. * 10 who receive the standard uncoated catheters used in routine patient care.
| Arm | Type | Receives |
|---|---|---|
| Standard of Care | Active comparator | Device: Standard of CareStandard of Care |
| M4D coated catheter | Experimental | Device: M4DExperimental |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- -
Key exclusion criteria (6 listed)
- • Patients under age 18.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| M4DCoated catheter | Device | M4D coated catheter |
| Standard of CareStandard of Care | Device | Standard of Care |
Primary outcome
The primary outcome is the percentage of catheter surface colonised by biofilm, calculated as (light / (light + dark) x 100% in measurement of stained samples using fluorescence microscopy.
Time frame: 30 days
The primary outcome is the percentage of catheter surface colonised by biofilm, calculated as (light / (light + dark) x 100% in measurement of stained samples using fluorescence microscopy.
1 secondary outcome
Secondary outcomes will be logging of events, including catheter blockage or presumed CAUTI.
Time frame: 30days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Aug 2022.
- Individual participant dataSharing planned: No
Related trials for Urinary Tract Infections
Recruiting
Diagnosis and Treatment of Urinary Tract Infection Using DNA Polymerase Chain Reaction Versus Urine Culture
Urinary Tract Infections
Active, not recruitingObservational study
Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR
Complicated Urinary Tract Infection
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
Recruiting
INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS
Drug Resistance, Microbial, Biomarkers
Not yet recruitingObservational study
Comparative Study of the Genomic Characteristics of Uropathogenic Escherichia Coli According to the Severity of Community-Acquired Urinary Tract Infections in Guadeloupe (COLIGENURI)
Urinary Tract Infections
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing M4D in people with Urinary Tract Infections, run by Camstent Ltd. at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary outcome is the percentage of catheter surface colonised by biofilm, calculated as (light / (light + dark) x 100% in measurement of stained samples using fluorescence microscopy. (time frame: 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2022.